Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluating the Immunogenicity and Safety of Quadrivalent Human Papillomavirus Recombinant Vaccine (Type 6, 11, 16, 18) in Healthy Chinese Female Subjects Aged 9 to 26 Years: A Phase 3, Open-label, Non-randomized Clinical Trial

NCT05027776 is registered in ClinicalTrials.gov with Shanghai Bovax Biotechnology Co., Ltd. as lead sponsor.

NCT NCT05027776
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05027776 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluating the Immunogenicity and Safety of Quadrivalent Human Papillomavirus Recombinant Vaccine (Type 6, 11, 16, 18) in Healthy Chinese Female Subjects Aged 9 to 26 Years: A Phase 3, Open-label, Non-randomized Clinical Trial
Lead sponsor
Shanghai Bovax Biotechnology Co., Ltd.
Phase
Phase 3
Overall status
Recruiting
Start date
September 15, 2021
Completion date
September 29, 2026
Enrollment
1,348 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cervical cancer stage iia, cin1, cin2, cin3, genital wart, hpv infections, vaginal cancer